An unprecedented year and the road ahead: A conversation with Giovanni Caforio, PhRMA Chairman and CEO of Bristol Myers Squibbnews2020-11-18T18:00:00+00:00November 18th, 2020|The Catalyst|
Just released: PhRMA members’ new clinical trial diversity principlesnews2020-11-18T13:00:00+00:00November 18th, 2020|The Catalyst|
Learning from history: How government price setting and other anti-innovation policies negatively impact biopharmaceutical R&Dnews2020-11-16T18:00:00+00:00November 16th, 2020|The Catalyst|
Deep dive: The issues that drove the 2020 votenews2020-11-13T17:56:49+00:00November 13th, 2020|The Catalyst|
Understanding the emergency use authorization process for COVID-19 vaccinesnews2020-11-12T14:00:00+00:00November 12th, 2020|The Catalyst|
Guest Post: Recognizing America’s Veteransnews2020-11-11T14:00:00+00:00November 11th, 2020|The Catalyst|
New video: See how strong IP protections lead to stronger treatments for patientsnews2020-11-09T15:00:00+00:00November 9th, 2020|The Catalyst|
PhRMA submits comments on ways to refocus the 340B program on America’s vulnerable patientsnews2020-11-02T20:52:48+00:00November 2nd, 2020|The Catalyst|
ICYMI – Addressing health inequities: Biopharmaceutical companies are rising to the occasionnews2020-11-02T19:00:00+00:00November 2nd, 2020|The Catalyst|
U.S. trade policy must prioritize American biopharmaceutical innovation and patient accessnews2020-11-02T18:00:00+00:00November 2nd, 2020|The Catalyst|
